About PREMIERPREMIER was a Phase 3, randomized, controlled trial in MTX-naïve patients with early moderate to severe RA. Patients received MTX, HUMIRA 40 mg eow or HUMIRA 40 mg eow plus MTX for two years of blinded treatment. The co-primary endpoints were ACR 50 response and mean change from baseline in mTSS at week 52 for the HUMIRA + MTX combination therapy arm versus the MTX monotherapy. Results of this trial demonstrated the radiographic, clinical and functional superiority of initial combination therapy over the individual monotherapies.About HUMIRA ® (adalimumab)
Abbott Announces Results Of Analysis Exploring The Use Of HUMIRA® (Adalimumab) In Simultaneously Achieving Three Key Treatment Goals For Rheumatoid Arthritis
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.